Advertisement

Topics

Companies Related to "AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study" [Most Relevant Company Matches] RSS

09:41 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study" found in our extensive corporate database of over 50,000 company records.

Showing "AMelioration Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study" Companies 1–25 of 972

Relevant

ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor [human]) for routine prophylaxis a...


Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can l...


ZymeQuest, Inc

ZymeQuest is developing and will manufacture and sell enzymatic conversion systems to regional blood centers for use in converting groups A, B and AB red blood cells to enzyme converted group O (ECO) red blood cells.Our enzyme conversion system consists of:Enzymes to convert non-O red cells to ECO red cells.Specific solutions and reagents needed to perform enzyme conversion.A fully automated devic...

Lev Pharmaceuticals

We are a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Our product candidates are based on C1-esterase inhibitor (C1-INH), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. We initiated a Phase III clinical trial of our lead product...

Arno Therapeutics, Inc.

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. In addition to AR-67, Arno's lead clinical compound is AR-12, a potentially first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway and induces autophagy and the endoplasmi...

Santarus, Inc. and Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST™ (RHUCIN® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein. The product is also under development f...

Biotie Therapies

Biotie Therapies is a drug development biotechnology company with a focus on dependence disorders, inflammatory diseases and thrombosis.The most advanced drugs in development are nalmefene for alcoholism (phase III) and impulse control disorders (phase II), monoclonal VAP-1 antibody and small molecule VAP-1 SSAO enzyme inhibitor for inflammatory diseases (late preclinical), and recombinant biohepa...

Antidote Therapeutics, Inc.

Antidote Therapeutics, Inc. is a biotechnology company with a portfolio of first-in-class nicotine-blocking drugs to treat diseases caused or worsened by nicotine. In addition to Buerger’s Disease, ATI-1013 is also being investigated for Critical Limb Ischemia and nicotine addiction, and the company has other product candidates that neutralize or eli...

Heron Therapeutics, Inc.

Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that nee...

ActiveSite Pharmaceuticals, Inc.

ActiveSite Pharmaceuticals, Inc., is a privately held, preclinical stage pharmaceutical company, located in the San Francisco Bay Area. The company utilizes proprietary lead discovery technology to discover new inhibitors for therapeutic enzyme targets in diseases with unmet medical need. Its lead program, an orally active small molecule plasma kallikrein ...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Enzyme System Products

Enzyme System Products synthesis and development of protease substrates, inhibitors, purified enzymes and specific antibodies.

AB Enzymes

AB Enzymes offers enzyme products for industrial applications worldwide. The Products range from food enzymes – e.g. for bakery products and beverages – through enzymes for feed to enzyme products for textile technology and the pulp and paper industry.AB Enzymes is represented in more than 50 countries with over 70 products. Apart from its headquarters in Darmstadt, the company also has its ow...

NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for intestinal failure associated with shor...

Innocrin Pharmaceuticals, Inc.

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer. VT-464 and the entire CYP17 inhibitor patent estate are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as we...

Enzyme Research Laboratories Ltd

Enzyme Research Laboratories Ltd is a leading specialist in the production and supply of high purity blood coagulation products. Over the last ten years it has provided invaluable support to scientists involved in haemostasis and thrombosis research

Biocatalysts Ltd

Biocatalysts was the first enzyme company to offer custom tailoring, you could say we were the catalyst that changed the enzyme industry from its inward looking production focus to a customer based approached. Now we are keeping one step ahead of our competitors by not only custom tailoring enzymes but your whole enzyme buying experience. How you want to contact us, specific documentation requirem...

ProCertus BioPharm, Inc.

ProCertus BioPharm is an oncology-based pharmaceutical company whose primary mission is to protect cancer patients against the side effects of chemotherapy and radiotherapy.ProCertus has established proof of concept in animal models for its product candidates, DermX, ProDermaCel™, and OralX, proprietary pharmaceuticals designed to reduce or eliminate the side effects associated with cancer thera...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Enzyme Services & Consultancy Ltd

Enzyme Services & Consultancy Ltd. (ESC) was set up in 1999 to be the only independent provider of information and services to users and manufacturers of industrial enzymes. Six years on we have grown from the 2 founders to a staff of 8 full-time scientists. We continue to grow and have recently doubled the size of our laboratories which are still based in Blackwood

Serenex

Serenex is an integrated oncology-focused drug discovery and development company. Our mission is to improve the lives of cancer patients by developing proprietary therapeutic and supportive care products. Our most advanced program, SNX-1012, is a product for chemotherapy and radiation-induced oral mucositis. This is scheduled to complete Phase 2 trials in Q1 2007. Our most advanced preclinical-sta...

Research Diets, Inc

Research Diets, Inc began producing and formulating custom purified-ingredient diets for lab animals. We have worked hand-in-hand with universities, CRO's, pharmaceutical companies, laboratories, non- profit and government institutions to provide diet solutions for specific diet induced disease models. One such model in the study of obesity led to the development of the "Original" High-Fat Diet se...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration of skin scarring and other fibrotic disorders. EXC 001 was co-discovered by Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Excaliard, and licensed to Excaliard Pharmaceuticals.

SGX Pharmaceuticals, Inc.

SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelog...


More From BioPortfolio on "AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks